Big Potential, Tiny Penny Stock
Little-known stock ready to disrupt the $4.37 trillion wellness market
Click here to download the full report.
Alexander Aravanis net worth and biography

Alexander Aravanis Biography and Net Worth

SVP of Illumina
Alex Aravanis Ph.D. serves as Chief Technology Officer of the Company. Dr. Aravanis brings almost 20 years of experience in leading research and development efforts, spanning basic research and technology development through late stage clinical development, and is returning to Illumina from GRAIL, Inc. which he co-founded, and serves as the Chief Scientific Officer and Head of Research and Development. At GRAIL, he led the teams developing its multi-cancer early detection test by combining high-intensity sequencing approaches of unprecedented breadth and depth, and the latest tools of data science and data engineering, including powerful approaches from machine learning, such as neural networks. He and the GRAIL team created one of the largest clinical study programs ever in genomic medicine to support development of its products. Prior to GRAIL, Dr. Aravanis served in R&D for Illumina and developed multiple technologies, including clinical assays and bioinformatic pipelines for the analysis of RNA and DNA from fixed tissues, whole exome analysis, massively parallel single cell transcriptomics and liquid biopsy using cell-free nucleic acids. Dr. Aravanis holds a B.S. in Electrical Engineering, Computer Science, and Physics Minor from the University of California, Berkeley, as well as an M.S. and Ph.D. in Electrical Engineering, and an M.D. from Stanford University.

What is Alexander Aravanis' net worth?

The estimated net worth of Alexander Aravanis is at least $647,544.42 as of February 22nd, 2023. Dr. Aravanis owns 2,922 shares of Illumina stock worth more than $647,544 as of March 22nd. This net worth evaluation does not reflect any other investments that Dr. Aravanis may own. Learn More about Alexander Aravanis' net worth.

How do I contact Alexander Aravanis?

The corporate mailing address for Dr. Aravanis and other Illumina executives is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. Illumina can also be reached via phone at (858) 202-4500 and via email at [email protected] Learn More on Alexander Aravanis' contact information.

Has Alexander Aravanis been buying or selling shares of Illumina?

During the past quarter, Alexander Aravanis has sold $1,088,992.52 of Illumina stock. Most recently, Alexander Aravanis sold 5,398 shares of the business's stock in a transaction on Wednesday, February 22nd. The shares were sold at an average price of $201.74, for a transaction totalling $1,088,992.52. Following the completion of the sale, the senior vice president now directly owns 2,922 shares of the company's stock, valued at $589,484.28. Learn More on Alexander Aravanis' trading history.

Who are Illumina's active insiders?

Illumina's insider roster includes Alexander Aravanis (SVP), Frances Arnold (Director), Charles Dadswell (SVP), Francis deSouza (CEO), Phillip Febbo (SVP), Jay Flatley (Director), Aimee Hoyt (SVP), Karen Mcginnis (CAO), Robert Ragusa (SVP), Mostafa Ronaghi (SVP), Sam Samad (CFO), Susan Tousi (SVP), and Mark Van Oene (SVP). Learn More on Illumina's active insiders.

Are insiders buying or selling shares of Illumina?

In the last year, insiders at the life sciences company sold shares 14 times. They sold a total of 18,673 shares worth more than $4,563,255.41. The most recent insider tranaction occured on March, 1st when SVP Aimee L Hoyt sold 3,917 shares worth more than $779,718.02. Insiders at Illumina own 0.1% of the company. Learn More about insider trades at Illumina.

Information on this page was last updated on 3/1/2023.

Alexander Aravanis Insider Trading History at Illumina

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/22/2023Sell5,398$201.74$1,088,992.522,922View SEC Filing Icon  
7/7/2022Sell539$200.00$107,800.003,346View SEC Filing Icon  
11/12/2021Sell361$386.35$139,472.35View SEC Filing Icon  
11/2/2021Sell2,926$412.78$1,207,794.28View SEC Filing Icon  
10/26/2021Sell2,926$423.00$1,237,698.00View SEC Filing Icon  
10/19/2021Sell2,926$411.82$1,204,985.32View SEC Filing Icon  
10/12/2021Sell2,926$409.21$1,197,348.46View SEC Filing Icon  
7/7/2021Sell539$477.59$257,421.01View SEC Filing Icon  
See Full Table

Alexander Aravanis Buying and Selling Activity at Illumina

This chart shows Alexander Aravanis's buying and selling at Illumina by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Illumina Company Overview

Illumina logo
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $221.61
Low: $218.55
High: $222.55

50 Day Range

MA: $209.65
Low: $193.75
High: $228.15

2 Week Range

Now: $221.61
Low: $173.45
High: $371.16


1,015,830 shs

Average Volume

1,458,294 shs

Market Capitalization

$35.01 billion

P/E Ratio


Dividend Yield



Big Potential, Tiny Penny Stock
Little-known stock ready to disrupt the $4.37 trillion wellness market
Click here to download the full report.